Angelini Pharma

Angelini Pharma, the pharmaceutical division of Angelini Group, is an integrated pharmaceutical company with a wide-ranging R&D department that has developed significant molecules such as trazodone and phenethylamine. Angelini Pharma is a leader in the healthcare field, leveraging the strengths and expertise of its new Angelini Pharma Rare Diseases AG Business Unit in mental health (including pain and rare diseases) to develop, manufacture, and commercialize gaboxadol for the potential treatment of Angelman Syndrome in Europe. Current research focuses on neurological disorders and pain, inflammation, and rare diseases, with a particular commitment to exploring new therapies for pediatric populations.